Cargando…

Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer

INTRODUCTION: The potential of oncogene-driven targeted therapy is perhaps most fully realized in non-small cell lung cancer (NSCLC), given the number of genomic targets and approved matched therapies. However, invasive tissue biopsy at the time of each disease progression may not be possible and is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villaflor, Victoria, Won, Brian, Nagy, Rebecca, Banks, Kimberly, Lanman, Richard B., Talasaz, AmirAli, Salgia, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341844/ https://www.ncbi.nlm.nih.gov/pubmed/27602770 http://dx.doi.org/10.18632/oncotarget.11801

Ejemplares similares

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
por: Schwaederle, Maria, et al.
Publicado: (2016)

Clinical utility of circulating cell-free DNA in advanced colorectal cancer
por: Pereira, Allan A. Lima, et al.
Publicado: (2017)

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis
por: Kim, Seung Tae, et al.
Publicado: (2017)

Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
por: Villaflor, Victoria M., et al.
Publicado: (2013)

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases
por: Mack, Philip C., et al.
Publicado: (2020)

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
por: Kato, Shumei, et al.
Publicado: (2019)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
por: Lanman, Richard B., et al.
Publicado: (2015)

Heuristic value-based framework for lung cancer decision-making
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay
por: Clifton, Katherine, et al.
Publicado: (2019)

The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy
por: Galvez, Carlos, et al.
Publicado: (2020)

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors
por: Piccioni, David E, et al.
Publicado: (2019)

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort
por: Lee, Jeeyun, et al.
Publicado: (2019)

A biocomposite-based rapid sampling assay for circulating cell-free DNA in liquid biopsy samples from human cancers
por: Koo, Bonhan, et al.
Publicado: (2020)

Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer
por: Cheng, Xianliang, et al.
Publicado: (2017)

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
por: Kim, Seung Tae, et al.
Publicado: (2015)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer
por: Roosan, Moom R., et al.
Publicado: (2021)

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
por: Jia, Jingquan, et al.
Publicado: (2018)

mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer
por: Cann, Gordon M., et al.
Publicado: (2012)

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA
por: Finkle, Justin D., et al.
Publicado: (2021)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

Liquid biopsy: blood‐based analyses of circulating cell‐free DNA in xenografts
por: Heidrich, Isabel, et al.
Publicado: (2022)

O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer
por: Hasina, Rifat, et al.
Publicado: (2013)

Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays
por: Ono, Shigeshi, et al.
Publicado: (2015)

Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy
por: Sato, Akemi, et al.
Publicado: (2018)

Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol
por: Sorber, Laure, et al.
Publicado: (2019)

Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma
por: Lyu, Xueying, et al.
Publicado: (2022)

Analysis of colorectal cancer‐related mutations by liquid biopsy: Utility of circulating cell‐free DNA and circulating tumor cells
por: Takeda, Kohki, et al.
Publicado: (2019)

Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma
por: Mihály, Dóra, et al.
Publicado: (2018)

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
por: Remon, Jordi, et al.
Publicado: (2020)

Mendelian randomization of circulating proteome identifies actionable targets in heart failure
por: Moncla, Louis-Hippolyte Minvielle, et al.
Publicado: (2022)

Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids
por: Okajima, Wataru, et al.
Publicado: (2017)

Liquid biopsy for esophageal cancer: Is detection of circulating cell‐free DNA as a biomarker feasible?
por: Yuan, Zuyang, et al.
Publicado: (2020)

Circulating Cell-Free DNA in Inflammatory Bowel Disease: Liquid Biopsies with Mechanistic and Translational Implications
por: Chuah, Cher Shiong, et al.
Publicado: (2023)

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
por: Pathak, Ranjan, et al.
Publicado: (2021)

The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer
por: Pharaon, Rebecca R., et al.
Publicado: (2021)

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
por: Patel, Hitendra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rfjen3dl8vlqi6f8m58kep9o9u